Market News & Trends
Genzyme Corporation Announces Drug Approval
Genzyme, a Sanofi company, recently announced that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO (teriflunomide) 14 mg as a new once-daily, oral treatment…
MethylGene Closes Substantial Private Placement
MethylGene Inc. recently announced it has completed its previously announced private placement of 179,690,970 units at a subscription price per unit of Cdn.$0.145 (the Subscription…
Teva to Focus on Smaller M&A
Teva Pharmaceutical Industries Ltd. is shifting away from the multi-billion dollar acquisitions that have defined its growth for the past decade, indicating acquisitions don't have…
XOMA Corporation Seeks to Sublicense Drug
XOMA Corporation recently announced the 837-patient Phase III PATH trial (Perindopril Amlodipine for the Treatment of Hypertension) has demonstrated the fixed-dose combination (FDC) of perindopril…
11/21/2012
Innovative Drugs to Transform Alzheimer's Disease Medication Market The patent expiry of all four existing EMEA-approved drugs for Alzheimer's disease (AD) by 2015 is likely…
Allergan to Acquire SkinMedica for $350 Million
Allergan, Inc. recently announced it has entered into a definitive agreement with SkinMedica, Inc. to acquire the privately held company's topical aesthetics skin care…
EFCG Calls for Mandatory Inspections of All Global API Manufacturing Sites
The European Fine Chemicals Group (EFCG) is proposing a global harmonization of the rules and regulations governing the manufacture of active pharmaceutical ingredients (APIs) to…
Innovative Drugs to Transform Alzheimer's Disease Medication Market
The patent expiry of all four existing EMEA-approved drugs for Alzheimer's disease (AD) by 2015 is likely to cause a steep decline in the growth…
Intarcia Therapeutics Secures Landmark $210-Million Financing
Intarcia Therapeutics, Inc. recently announced the simultaneous completion of two financings with total proceeds of $210 million, the largest sum to be raised by a…
Jubilant HollisterStier Secures Significant Contracts
Jubilant HollisterStier, a subsidiary of Jubilant Life Sciences, recently announced its Contract Manufacturing & Services division has recently secured over $100 million in contracts with…
Nanoparticle Technology Facilitates Cancer Metastasis Research
NanoSight, leading manufacturers of unique nanoparticle characterization technology, recently reported on the breakthrough cancer metastasis research of Dr. Hector Peinado Selgas and Dr. David…
Novartis Expects 14 New Blockbusters
Novartis recently provided an update on its leading Research and Development (R&D) pipeline and plans for turning these assets into commercial success to provide the…
Patheon to Acquire Banner Pharmacaps
Patheon Inc. recently announced it has entered into a definitive agreement with VION N.V. to acquire Banner Pharmacaps, a specialty pharmaceutical business dedicated to the…
Regulus Therapeutics Secures $80.9 Million
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, recently announced its financing activity that the company expects…
Sun Pharmaceutical to Purchase PhotoDynamic Company for $230 Million
Sun Pharmaceutical Industries Limited and DUSA Pharmaceuticals, Inc. recently announced they have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a…
Ziarco Pharma Acquires Pfizer Drugs, Secures Financing
Ziarco recently announced the closing of an initial $6-million tranche of Series A financing totalling $27 million. The round was led by Biotechnology Value Fund…
11/14/2012
A Note to The Pharmaceutical Industry Upon The Re-Election of Barack Obama By: Matthew Herper, Forbes Staff, mherper@forbes.com I've covered the drug industry for 12…
A Note to The Pharmaceutical Industry Upon The Re-Election of Barack Obama
By: Matthew Herper, Forbes Staff, mherper@forbes.com I've covered the drug industry for 12 years, long enough to know that it is no monolith but a…
10/30/2012
Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis…
Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan
Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis (PsA) patients in need of additional therapy beyond standard of…
